Why the study?
Class III antiarrhythmic drugs are commonly used to treat atrial fibrillation, but their specific effects on myocardium in the pulmonary vein orifices required investigation.
Do class III antiarrhythmic drugs (Sotalol and Refralon) alter the functional refractory period and action potential duration in rat pulmonary vein orifice myocardium?
Do class III antiarrhythmic drugs (Sotalol and Refralon) alter the functional refractory period and action potential duration in rat pulmonary vein orifice myocardium?
Refralon decreases the vulnerability window in pulmonary vein myocardium compared to Sotalol, potentially explaining differences in their antiarrhythmic efficacy.
Answers are grounded in this paper and cite their sources.
Class III antiarrhythmic effects on pulmonary vein ostia myocardium remain hypothesis-generating; leaves open any role in AF management.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yu. V. Egorov (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: